TOday’s Movers: AstraZeneca (LON:AZN) Stock Rating Reiterated by equity analysts Barclays; GBX 4400 Target Price Indicates -0.80% Potential


AstraZeneca (LON:AZN) Rating Reaffirmed

Barclays now has a GBX 4400 target on the 55.67B GBP market cap company or -0.80% downside potential. In analysts note published on 16 December, AstraZeneca (LON:AZN) shares have had their “Underweight” Rating has decided to restate by professional analysts at Barclays.

From a total of 28 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 95.63 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 71.27 with a 8.69% above today’s (GBX 4438.5) stock price. AstraZeneca PLC was the topic of 122 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 10 with “Market Perform” rating. UBS maintained shares with “Buy” rating and GBX 5000 target share price in a report from a November 25. Jefferies maintained AZN stock in a recent report from December 7 with “Buy” rating. Credit Suisse maintained the rating on November 24. Credit Suisse has a “Underperform” rating and a GBX 4000 price target on shares. Finally, Morgan Stanley upgraded the stock to “Overweight” rating in a report issued on a December 1.

Approximately 456,720 shares of stock traded hands. AstraZeneca plc (LON:AZN) has declined 0.28% since May 19, 2015 and is downtrending. It has outperformed by 2.34% the S&P500.

TOday’s Movers: AstraZeneca (LON:AZN) Stock Rating Reiterated by equity analysts Barclays; GBX 4400 Target Price Indicates -0.80% Potential

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 55.67 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.14 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”